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Predisposition factors for pelvic ﬂoor disorders (PFDs), including pelvic organ prolapse (POP), stress urinary incontinence (SUI), urge
urinary incontinence (UUI), and hernias, are not well understood. We assessed linkage evidence for PFDs in mostly sister pairs who
received treatment for moderate-to-severe POP. We genotyped 70 affected women of European descent from 32 eligible families with
at least two affected cases by using the Illumina 1 million single-nucleotide polymorphism (SNP) marker set. Parametric linkage analysis
with general dominant and recessive models was performed by the Markov chain Monte Carlo linkage analysis method, MCLINK, and
a set of SNPs was formed, from which those in high linkage disequilibrium were eliminated. Signiﬁcant genome-wide evidence for
linkage was identiﬁed on chromosome 9q21 with a HLOD score of 3.41 under a recessive model. Seventeen pedigrees (53%) had at least
nominal evidence for linkage on a by-pedigree basis at this region. These results provide evidence for a predisposition gene for PFDs on
chromosome 9q.Pelvic ﬂoor disorders (PFDs), including pelvic organ
prolapse (POP) (MIM 176780), stress urinary incontinence
(SUI), urge urinary incontinence (UUI), and hernias, are
seen in women of all ages and are a major public health
concern. One in nine women will undergo surgery for
these disorders in her lifetime,1 and of these, one third
will undergo repeated surgeries. Many more women are
affected by POP and incontinence but manage their symp-
toms without surgery.2
The etiology of PFDs is most likely multifactorial. Risk
factors typically focus on defects in the pelvic ﬂoor muscu-
lature or connective tissue weakness. Childbirth is the
most studied risk factor;3 vaginal delivery, especially with
forceps, increases the risk of urinary incontinence, but
cesarean delivery is not entirely protective.4 Other risk
factors include increased age, smoking, and chronic
increased intra-abdominal pressures such as occupational
lifting, obesity, and chronic constipation.3 However, these
environmental risk factors fail to fully explain the patho-
physiology of PFDs. Severe POP and SUI have been
observed in nulliparous women,5 whereas other highly
parous women do not develop POP or SUI.
Several studies have investigated a possible genetic
predisposition for PFDs. Epidemiology surveys have found
that women with urinary incontinence were more likely
to have family members with incontinence,6–9 and genetic
effects may account for as much as 40% of the total
variance of SUI and POP.10 Recent candidate gene studies
have focused on genes related to skeletal muscle myosin,11
p27/kip1 (cyclin-dependent kinase inhibitor 1B [MIM
600778]),12 and the basement membrane protein laminin
(LAMC1 [MIM 150290])13.
To better understand the genetics of POP, this study was
undertaken with the purpose of determining whether
there is linkage evidence for a predisposition gene(s) forPOP in a large set of affected sister pairs with PFDs. To
our knowledge, this study is the ﬁrst linkage study of
high-risk POP pedigrees.
Women who underwent surgical repair of a PFD in the
urogynecology service at the University of Utah from 1996
to 2006 were invited to participate in this study (n ¼ 533
women). Of these, 297 had surgery for POP only and 256
had surgery for both POP and SUI. These probands
completed a demographic questionnaire about age at onset
of symptoms, childbirth history, family history, and poten-
tial clinical markers such as striae and joint mobility. The
probands contacted their sisters for permission to receive
amailquestionnaire for evidenceof aPFD.Sister recruitment
began in 2002. Sisters who agreed to participate completed
the same demographic questionnaire as the probands and
completed a 43-question standardized survey for PFDs, the
pelvic ﬂoor distress inventory (PFDI).14 The PFDI has been
validated as a PFD symptom screen in at-risk populations.15
TheUniversity ofUtah Institutional ReviewBoard approved
this study prior to enrollment, and informed consent was
obtained for every participating subject.
Sisters were identiﬁed as ‘‘probably affected’’ or ‘‘unlikely
affected’’ on the basis of questionnaire results or surgical
histories. In a few families, other close female relatives
were screened. Women who were termed ‘‘probably
affected’’ were examined for POP via a standardized clinical
assessment for POP, the POP-Q,16 as well as for SUI andUUI
via the full bladder standing cough stress test (CST) or diary
as appropriate. If a relative was unable to travel to complete
the POP-Q or CST, documentation of treatment for a PFD,
which was usually surgery for the condition, was required.
Finally, all affected individuals underwent blood sampling
for DNA analysis.
Of the 553 total female probands, 195 had no living
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respond to the study invitation; and 94 declined, with-
drew, or did not have a sister who agreed to participate.
Our ﬁnal sample included 124 probands who provided
information on 1–8 sisters per family and additional
female relatives. A total of 209 women were sampled and
phenotyped.
For linkage analysis, we deﬁned POP cases by a rigorous
phenotype deﬁnition. ‘‘Affected’’ individuals were those
who received treatment for moderate-to-severe POP,
usually stage III or IV, and in most cases the treatment
was surgery. In the POP-Q staging system, stage III repre-
sents prolapse of the pelvic organs more than 1 cm beyond
the hymeneal ring or vaginal opening; stage IV represents
complete prolapse of the vagina and pelvic organs.
Eligible families had to have at least two affected rela-
tives meeting our strict phenotype deﬁnition. Although
probands were identiﬁed by having a PFD surgery at the
University of Utah, relatives were scattered across the
United States.
We identiﬁed 32 eligible families informative for linkage
analysis in which the largest number of affected, geno-
typed individuals per family was three. These families
included a total of 70 affected individuals meeting our
strict phenotype criteria, all of whom were of European
descent. The majority of families (n ¼ 25, 78%) contained
two affected sisters, ﬁve families had three affected sisters,
and two families contained more distant relatives. One
of the extended pedigrees consisted of an aunt-niece pair.
The niece has a sister who is also affected with POP,
but the sister never received treatment for POP. The other
extended pedigree consisted of two affected sisters and
their affected aunt. All deﬁned POP cases used for this
study received a physical exam by a physician at the
University of Utah Hospital and Clinics for conﬁrmation
of diagnosis.
Table 1 summarizes the clinical characteristics of the
sampled women. Most women had given birth to at least
one child; only one woman in this sample was nulliparous.
Approximately half (n ¼ 33 of 64 with body mass index
[BMI] information) of the women were overweight or
obese (BMI > 25 kg/m2). A substantial percentage of the
women meeting our strict phenotype criteria for POP
had also received treatment for SUI (64.3%), UUI
(31.4%), and/or hernias (5.7%).
Samples for participating affected women in eligible
families were genotyped with the Illumina 1 million
single-nucleotide polymorphism (SNP) set. If markers are
in strong linkagedisequilibrium, linkage analysis of densely
typed markers can lead to an inﬂation of linkage statistics
and an excess of false positive results.17 Therefore, we
analyzed a pruned set of SNPmarkers (n¼ 27,157) inwhich
markers in high linkage disequilibrium were eliminated.
These 27,157 markers had a minimum spacing of 0.1 cM,
a minimum heterozygosity of 0.3, and a maximum r2 of
0.16 over a sliding 500,000 bp window in the publicly
available HapMap CEPH/Utah (CEU) data and exceeded
an individual call rate of 98% for genotyped subjects.The AmWe used the integrated genetic map of Duffy18 as our
backbone map and linearly interpolated additional SNPs
with Build 35.1 of the human genome sequence to derive
our genetic map. Allele frequencies were estimated directly
from observation of all genotyped individuals at each
locus.
We performed a linkage analysis on the linkage subset of
markers with the multipoint Markov chain Monte Carlo
(MCMC) linkage method MCLINK.19 MCLINK allows for
fully informative multilocus linkage analysis on large
extended pedigrees and has been used previously for
identiﬁcation of candidate genomic regions for a number
of complex diseases.20–22 Because the mode of inheritance
of POP is unknown, we performed a parametric analysis
with both general dominant and recessive models. Pheno-
types of all individuals not termed ‘‘affected’’ were consid-
ered ‘‘unknown,’’ and these individualswerenot genotyped
in the present study. Although individuals termed
unknown did not meet strict study criteria for POP, many
of thewomenwere affectedwith other types of PFDs.Males
were also considered unknown because, though they
cannot express the phenotype, theymay be genetic carriers
of a predisposition gene(s).
Because PFDs are most likely complex diseases and prob-
ably arise from multiple heterogeneous loci, we report
heterogeneity LOD (HLOD) scores rather than LOD scores.
HLOD scores more accurately reﬂect the true position of
a linkage peak and have been shown to be more powerful
than homogeneity LOD scores and model-free methods
under conditions of heterogeneity.23,24
Signiﬁcance was determined by the Lander and Kru-
glyak25 genome-wide criteria. Suggestive linkage evidence
was deﬁned by a LOD score R 1.86, and signiﬁcant
evidence was deﬁned by a LOD score R 3.30. Speciﬁc
pedigrees were also identiﬁed for chromosomal regions
that exceeded HLOD R 3.30 and had individual LOD
scores > 0.5, which represents a nominal, uncorrected
p < 0.05 for an individual pedigree.
Genome-wide linkage results for all pedigrees are
displayed in Figure 1. The maximum HLOD statistic
observed was 3.41 (rs11139451) at chromosome 9q21,
Table 1. Clinical Characteristics of Sampled Affected POP
Individuals
Characteristics Affected Individuals1 (n ¼ 70)
Age at diagnosis (yrs): mean5 SD
(range)
53.65 13.0 (27–75); n ¼ 53
Parity: median; (range) 4 (0–12); n ¼ 68
BMI kg/m2: mean5 SD (range) 26.35 4.4 (17–43); n ¼ 64
POP-Q stage III 30; n ¼ 66
POP-Q stage IV 11; n ¼ 66
Primary treatment for SUI 36
Treatment for Recurrent SUI 9
Treatment for OAB 22
Hernia 4
1 Data were not available for all cases. If data were not available for all
cases, total number of cases (n) is reported.erican Journal of Human Genetics 84, 678–682, May 15, 2009 679
Figure 1. Genome-wide Linkage Results
Chromosome number shown on the horizontal axis; HLOD score on the vertical axis. Red, recessive model; blue, dominant model.assuming a recessive model. This meets the Lander and
Kruglyak25 genome-wide signiﬁcance criterion accounting
for a dense marker map. All markers between rs4077632
(80,353,293 bp) and rs10868525 (88,807,848 bp) in the
chromosome 9q21 region exceeded HLOD > 1.86. Seven-
teen of the 32 pedigrees attained nominal linkage evidence
(i.e., HLOD > 0.5) on a by-pedigree basis for the region.
The highest HLOD score per pedigree was 1.18, which
was observed for two pedigrees, each with three affected
sisters. Suggestive linkage evidence was also noted on
chromosome 9q31 (maximum HLOD ¼ 1.90), which is
approximately 17 Mb away from 9q21, and chromosome
1q42 (maximum HLOD ¼ 1.89), assuming a recessive
model.
As secondary conﬁrmation of the signiﬁcant chromo-
some 9q21 result, we reanalyzed the data by using the
linkage package Merlin,26 which computes exact HLOD
scores via sparse binary trees. We obtained a maximum
HLOD score of 3.42, which is nearly identical to our
reported MCLINK results. We also empirically validated
our results by using the recently proposed latent p value
method27 as implemented by Alun Thomas with 5000
independent simulations. The median distribution of
the p value via the latent p method was 0.051 under the680 The American Journal of Human Genetics 84, 678–682, May 15general recessive model on a genome-wide basis, which is
in close agreement with the Lander and Kruglyak25
genome-wide signiﬁcance criterion.
There are only a limited number of previous studies that
have examined the role of genetics for PFDs. We are aware
of only one other linkage analysis that has been reported to
date. Nikolova et al.13 studied a single Filipino family with
six affected individuals of mixed PFD phenotypes (i.e., POP
and/or hernia) aged <55 years. They identiﬁed ten linkage
regions with LOD scores near 1.5, the maximum expected
for this family size and marker density. However, none of
the linkage signals were on chromosome 9q.
Several other studies have compared differential gene
expression between women with and without a PFD via
biopsy specimens from one of the pelvic ﬂoor muscles.
Caution must be exercised when interpreting these
studies, because many are underpowered. Visco and
Yuan11 compared gene expression in pubococcygeus
muscle biopsy specimens from ﬁve patients with stage III
or stage IV POP and ﬁve control subjects without prolapse.
They identiﬁed 111 genes that were underexpressed and
120 genes that were overexpressed after correcting for
background intensity levels; however, none were in the
chromosome 9q21 region. Hundley and colleagues28, 2009
observed signiﬁcant differences in gene expression in the
pubococcygeus muscle for two speciﬁc genes (MYH3
[myosin, heavy chain 3, skeletal muscle, embryonic]
[MIM 160720] on chromosome 17p13 and MyBP-h
[myosin-binding protein h] [MIM 160795] on chromo-
some 1q32) in 17 women with stage III or stage IV POP
and 23 controls with minimal to no prolapse. Bukovsky
and coworkers12 observed differences in p27/kip1 (chromo-
some 14q) expression levels from the levator ani muscle in
22 symptomatic patients with SUI and/or POP compared
to nine asymptomatic women. Results from these gene
expression studies are all limited to the speciﬁc tissue
studied and cannot be generalized to all pelvic ﬂoor
muscles. Our present study focuses on germline mutations
fromDNA obtained from blood; thus, our results are not in
discrepancy with these previous reports.
There are a number of genes in the chromosome 9q21
region that have a known protein function in muscle or
have been observed to be highly expressed in muscle.
They include: TLE4 (Transducin-like Enhancer of Split 4
[MIM 605132]), TLE1 (Transducin-like Enhancer of Split 1
[MIM 600189]), UBQLN1 (Ubiquilin 1 [MIM 605046]),
MAK10, and GOLM1. None of these genes has been previ-
ously studied as a candidate gene for PFDs.
In conclusion, we have found signiﬁcant linkage
evidence for a predisposition gene for PFDs on chromo-
some 9 by using the largest collection of families with
POP reported to date. These linkage results are remarkable
for the strength of signal obtained on chromosome 9q21
and a large percentage of our eligible families (n ¼ 17,
53%) showing evidence of linkage to the chromosome
9q21 region. Although this study focused on deﬁning cases
by POP severity status, many of the women were also
affected with varying degrees of SUI, UUI, and/or hernias.
Hence, these results cannot deﬁnitively identify a chromo-
somal region that predisposes one to POP. We also note
that our results are premature to suggest that all PFDs share
a common genetic predisposition, although epidemiolog-
ical studies suggest overlap of the PFD subcomponents.29
We are in the process of collecting and genotyping addi-
tional high-risk PFD pedigrees and plan in the future to
examine each PFD subcomponent separately, and we will
include in our analysis older, unaffected females in these
high-risk pedigrees to strengthen our conclusion that
a presumed disease locus causes disease in familial cases
and not in unaffected cases. Our results do not dispute
that PFDs are probably multifactorial diseases with contri-
butions from both genetic and environmental factors; we
note that not all of our pedigrees linked to the chromo-
some 9q21 region. Environmental factors and more
common risk alleles identiﬁed through association
analysis or other techniques may also play a role in PFD
predisposition. If our results are conﬁrmed, they can direct
future gene localization efforts. Knowledge of genetic
susceptibility may provide insight into the pathogenesis,
prevention, and intervention of this condition through
a genetic screen.The AmAcknowledgments
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